A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to the standard treatments. It will also learn about the safety of this new combination antibiotic treatment when compared to the standard treatments. The main questions it aims to answer are:
* How well does Arm D treat mycobacterium abscessus pulmonary disease?
* What side effects does Arm D cause when used to treat mycobacterium abscessus pulmonary disease? Researchers will compare Arm D to the current standard of care treatments to see if Arm D treats mycobacterium abscessus pulmonary disease better and if it will cause less side effects.
Participants will:
* Be screened and recruited to the FORMaT adaptive platform trial (NCT04310930)
* Be given Arm D for 4 weeks or standard of care treatments for 6 weeks.
* Be reviewed by the study doctors weekly for checkups and tests.
* Provide respiratory samples (sample coughed up from the chest), respond to quality-of-life questionnaires, have CT lung scans and blood tests.

开始日期2027-04-01

申办/合作机构

The University of Queensland

[+1]

ChiCTR2500112822

/ Recruiting早期临床1期IIT

An Exploratory Clinical Study on the Early Efficacy and Safety of JDB0131 Benzensulfonate Tablets in Patients with Multidrug-Resistant Tuberculosis

开始日期2025-11-20

申办/合作机构

北京威斯克生物医药科技有限公司

[+1]

NCT07228702

/ Enrolling by invitation临床1期IIT

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection: An Open Label Individual Patient Study

This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease

开始日期2025-11-01

申办/合作机构

Vancouver Coastal Health

100 项与氯法齐明相关的临床结果

登录后查看更多信息

100 项与氯法齐明相关的转化医学

登录后查看更多信息

100 项与氯法齐明相关的专利（医药）

登录后查看更多信息

2,071

项与氯法齐明相关的文献（医药）

2026-03-01·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Co-administering clofazimine with infant formula enhances its oral bioavailability in rats and pigs

Article

作者: Huang, Shouyuan ; Offersen, Simone Margaard ; Zann, Vanessa ; Boyd, Ben J ; Ponsonby-Thomas, Ellie ; Thymann, Thomas ; Eason, Thomas ; Salim, Malinda ; Pham, Anna C

Milk-based formulations have been proposed as enabling formulations for the delivery of poorly water-soluble drugs to children due to their safety, dose versatility and ability to improve drug solubilisation through the digestion process. In this study the feasibility of using commercially available infant formula as an enabling formulation to enhance the solubilisation and oral bioavailability of clofazimine, a poorly soluble lipophilic drug, following oral administration was investigated. The solubilisation of crystalline clofazimine in digesting infant formula was assessed in vitro using synchrotron small-angle X-ray scattering. An in vivo pharmacokinetic study was then conducted to determine the oral bioavailability of a suspension of clofazimine in infant formula compared to a lipid-free aqueous suspension in both a rat and piglet animal model. Clofazimine administered in infant formula produced significantly higher plasma concentrations than the aqueous vehicle and resulted in comparable enhancements in relative oral bioavailability in both the piglet (235%) and rat animal models (256%). Results from this study demonstrated that infant formula was an effective enabling formulation, with a positive correlation between improved drug solubilisation during in vitro digestion of infant formula and enhanced in vivo drug exposure following oral administration. Infant formula therefore offers an inexpensive and scalable formulation approach for improving the bioavailability of paediatric drugs, like clofazimine, and enabling the treatment of infections in children.

2026-03-01·CLINICAL MICROBIOLOGY AND INFECTION

A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in China

Article

作者: Qian, Yuan ; Xing, Yajiao ; Xiao, Mingying ; He, Zebao ; Zhang, Yena ; Li, Jinlan ; Wang, Jing ; Feng, Shun ; Chen, Yu ; Wu, Qianhong ; Li, Yiming ; Zhang, Wenhong ; Shi, Jichan ; Yu, Hongying ; Lan, Yuanbo ; Yi, Hengzhong ; Zhang, Yungui ; Liu, Haiqing ; Li, Yang ; Chen, Yuanyuan ; Luo, Jianfeng ; Zhou, Yong ; Zhao, Yanlin ; Chen, Bin ; Sun, Feng ; Huang, Ya ; Wei, Xiaolin ; Cai, Cui ; Zhang, Yilin ; Xu, Lin

OBJECTIVES:

Despite advancements in shorter, oral regimens for drug-resistant tuberculosis, more options are needed to extent patient benefits. We conducted a trial to evaluate the noninferiority of an all-oral regimen compared with the injectable-containing regimen.

METHODS:

In an open-label, randomized noninferiority trial in China, participants with rifampicin-resistant pulmonary tuberculosis were assigned 1:1 to a 6- to 9-month all-oral regimen (levofloxacin, linezolid, cycloserine, clofazimine and/or pyrazinamide) and a 9-month injectable-containing control regimen. The primary outcome was a favourable outcome at 84 weeks after treatment initiation, defined by two consecutive, negative cultures with no previous unfavourable outcome, using a noninferiority margin of 10%.

RESULTS:

Between 2 June 2020, and 1 December 2021, 660 participants were enrolled and 354 underwent randomization. A total of 312 and 260 participants were included in the modified intention-to-treat and the per-protocol analysis, respectively. In the modified intention-to-treat analysis, 76.1% of participants in the oral group and 63.7% of those in the control group had a favourable outcome at 84 weeks (difference, 12.4%; 95% CI, 2.4-22.5%; noninferiority p < 0.0001). In the per-protocol analysis, 84.4% of participants in the oral group and 73.5% of participants in the control group had a favourable outcome (difference, 10.9%; 95% CI, 1.1-20.7%; noninferiority p < 0.0001). Grade 3 to 5 adverse events occurred in 69.1% of participants in the control group and 59.5% in the oral group. The most common grade 3 to 5 adverse events were QTcF (corrected QT interval calculated with Fridericia's formula) prolongation, affecting 44.6% of participants in the control group and 29.5% of participants in the oral group. Hepatobiliary disorder occurred more frequently in the control group (21.7%) compared with the oral group (7.5%).

CONCLUSIONS:

The all-oral regimen was noninferior to the 9-month injectable-containing regimen, offering an alternative for patients lacking access to bedaquiline, delamanid or pretomanid. However, its efficacy against the latest WHO-recommended bedaquiline-containing regimens requires further validation.

2026-03-01·Respirology Case Reports

Type 2 Lepra Reaction Following Antituberculosis Treatment Initiation in an Elderly Male With Coexisting Hansen's Disease: A Case Report

Article

作者: Ysabel Regina H. Ortiz ; Cary Amiel G. Villanueva ; Winlove P. Mojica ; Albert B. Albay Jr

ABSTRACT:

Tuberculosis and leprosy coinfection is increasingly rare even in endemic areas. We report a 70‐year‐old male presenting with fever and malaise. Pulmonary tuberculosis was suggested by chest computed tomography scan and confirmed on polymerase chain reaction testing of bronchial wash specimens. Skin punch biopsies were consistent with lepromatous Hansen's disease. After initiating isoniazid, rifampicin, pyrazinamide and ethambutol, he developed new erythematous patches and plaques on the lower extremities and required supplemental oxygen. Erythema nodosum leprosum was diagnosed. Intravenous hydrocortisone, dapsone and clofazimine were started, and clinical improvement and decreased inflammatory markers followed. The patient was discharged with a 20‐week course of prednisone and multidrug treatment for drug‐susceptible pulmonary tuberculosis and leprosy. Concomitant Hansen's disease should be considered when treating patients for tuberculosis especially in areas where both are prevalent as different long‐term multidrug regimens are required.

项与氯法齐明相关的新闻（医药）

2026-03-26

·北京医学感染与传染研究

柳叶刀传染病学 26卷 1-4期（2026年3月26日更新）

THE LANCET Infectious Diseases. Volume 26Number 1 柳叶刀传染病学 26卷 1期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Urgent need for infection prevention and control in prisons 监狱中感染预防和控制的迫切需求 The Lancet Infectious Diseases The Lancet Infectious Diseases Vol 26(1):p1 COMMENT（述评） 2 Now is the time to integrate serology into routine infectious disease surveillance 现在是时候将血清学纳入常规传染病监测了 Simon Cauchemez The Lancet Infectious Diseases Vol 26(1):p2 3 Reassessing sotrovimab's role in COVID-19: insights and implications 重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示 Daniele Focosi,Fabrizio Maggi The Lancet Infectious Diseases Vol 26(1):p3 4 Shaping opportunities for future clinical trials in tuberculosis 为未来结核病临床试验创造机会 Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich The Lancet Infectious Diseases Vol 26(1):p5 5 Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda 乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化 Arjen M Dondorp The Lancet Infectious Diseases Vol 26(1):p6 6 A safe start for PfSPZ Vaccine, but efficacy in children remains elusive PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸 Nicholas Aderinto,Temitomi Jane Oyedele The Lancet Infectious Diseases Vol 26(1):p8 7 Rifasutenizol-based triple therapy for Helicobacter pylori infection 以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染 Jinnan Chen,Hong Lu The Lancet Infectious Diseases Vol 26(1):p9 8 The smallest faith 最渺小的信念 Steven A Pergam The Lancet Infectious Diseases Vol 26(1):p11 9 Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease 新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标 Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson The Lancet Infectious Diseases Vol 26(1):p13 10 Strengthening global preparedness and response to arboviral disease threats: a call to action 加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁 WHO Global Arbovirus Initiative Technical Advisory Group 世界卫生组织全球虫媒病毒倡议技术咨询小组 The Lancet Infectious Diseases Vol 26(1):p15 11 Introducing our cover artist for 2026: Daria Lada 介绍我们2026年的封面艺术家：达里亚·拉达 Marco De Ambrogi The Lancet Infectious Diseases Vol 26(1):p17 Correspondence（读者来信） 12 Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2 新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况 Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann The Lancet Infectious Diseases Vol 26(1):e1 13 Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响 Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens The Lancet Infectious Diseases Vol 26(1):e3 14 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致 Nader Ebrahimi,Amir Ghaemi The Lancet Infectious Diseases Vol 26(1):e6 15 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复 Frank Aarestrup,Marion Koopmans The Lancet Infectious Diseases Vol 26(1):e7 16 Time to tackle vaccine–HLA associations with artificial intelligence 是时候用人工智能解决疫苗-人类白细胞抗原关联问题了 Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington The Lancet Infectious Diseases Vol 26(1):e8 Corrections（更正） 17 Correction to Lancet Infect Dis 2025; published online Oct 29. 《柳叶刀-传染病》2025年更正；在线发表于10月29日 https://doi.org/10.1016/S1473-3099(25)00466-9 The Lancet Infectious Diseases Vol 26(1):e9 18 Correction to Lancet Infect Dis 2025; published online Oct 27. 《柳叶刀-传染病》2025年更正；在线发表于10月27日 https://doi.org/10.1016/S1473-3099(25)00546-8 The Lancet Infectious Diseases Vol 26(1):e9 19 Correction to Lancet Infect Dis 2025; 25: 1084–96 《柳叶刀-传染病》2025年更正；25卷：1084-1096页 The Lancet Infectious Diseases Vol 26(1):e9 20 Correction to Lancet Infect Dis 2025; published online Nov 10. 《柳叶刀-传染病》2025年更正；在线发表于11月10日 https://doi.org/10.1016/S1473-3099(25)00550-X The Lancet Infectious Diseases Vol 26(1):e9 Newsdesk（新闻台） 21 Highlights of IDWeek 2025 2025年IDWeek亮点 Phoebe Hall The Lancet Infectious Diseases Vol 26(1):e10 22 WHO publishes update on global antibiotic resistance 世界卫生组织发布全球抗生素耐药性最新情况 Timothy Jesudason The Lancet Infectious Diseases Vol 26(1):e11 23 European Commission to fund new medicines for dengue 欧盟委员会资助登革热新药研发 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):e12 24 Second report from the UK Covid-19 Inquiry 英国新冠肺炎调查第二次报告 Talha Burki The Lancet Infectious Diseases Vol 26(1):e13 25 Infectious disease surveillance update 传染病监测最新情况 Cahal McQuillan The Lancet Infectious Diseases Vol 26(1):e14 26 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases Vol 26(1):e15 Obituary（讣告） 27 Jean Louis Abdourahim Ndiaye 让·路易斯·阿卜杜拉希姆·恩迪亚耶 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):p19 Profile（人物介绍） 28 Fortunate Machingura—tackling climate change and disease 福图纳特·马辛古拉——应对气候变化与疾病 Tony Kirby The Lancet Infectious Diseases Vol 26(1):p20 Media Watch（媒体观察） Book（书籍） 29 The social and political drivers behind pandemics 大流行背后的社会和政治驱动因素 Emma Louise Fabiani The Lancet Infectious Diseases Vol 26(1):p21 Articles（论著） 30 Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study 新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究 Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek The Lancet Infectious Diseases Vol 26(1):p22 31 Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验 RECOVERY Collaborative Group RECOVERY协作组 The Lancet Infectious Diseases Vol 26(1):p34 32 A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial 含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验 John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team The Lancet Infectious Diseases Vol 26(1):p46 33 Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories 2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析 Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar The Lancet Infectious Diseases Vol 26(1):p55 34 Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial 乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验 Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka The Lancet Infectious Diseases Vol 26(1):p67 35 Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial 加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验 Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller The Lancet Infectious Diseases Vol 26(1):p79 36 Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究 Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda The Lancet Infectious Diseases Vol 26(1):p91 37 Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial 以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验 Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group The Lancet Infectious Diseases Vol 26(1):p101 Series（专题研讨会） 38 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Innovation in active and passive immunisation of people who are immunocompromised: a call to action 免疫功能低下人群主动和被动免疫接种的创新：行动呼吁 Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa The Lancet Infectious Diseases Vol 26(1):e16 39 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship 应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理 Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo The Lancet Infectious Diseases Vol 26(1):e30 Review（综述） 40 Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project 揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述 Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro The Lancet Infectious Diseases Vol 26(1):e49 Personal View（个人观点） 41 Azithromycin mass drug administration: balancing survival benefits and risks in children 阿奇霉素大规模药物给药：平衡儿童生存益处与风险 Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro The Lancet Infectious Diseases Vol 26(1):e62 Clinical Picture（临床影像） 42 Unexpected finding in a 17-year-old female undergoing screening colonoscopy 17岁女性接受筛查结肠镜检查时的意外发现 Ziheng Calvin Xu,Ethan Tan,Mayur Garg The Lancet Infectious Diseases Vol 26(1):e75 THE LANCET Infectious Diseases. Volume 26Number 2 柳叶刀传染病学 26卷 2期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Call for letters 征稿启事 The Lancet Infectious Diseases The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111 Comment（述评） 2 Long COVID is here to stay—even in children 长期新冠症状将持续存在——即使在儿童中亦是如此 Danilo Buonsenso The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112 3 Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment 利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用 Ming Hong Choi,Ivan Fan Ngai Hung The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113 4 A new monoclonal in the arMAMentarium against malaria 抗疟“武器库”中的新型单克隆抗体 Freia-Raphaella Lorenz,Matthew B B McCall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115 5 Household transmission of mpox in Africa: limited in adults but more prevalent in children 非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍 Oriol Mitjà,Michael Marks The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117 6 The lasting lessons of mpox: infection, vaccination, and immune memory 猴痘带来的持久教训：感染、疫苗接种和免疫记忆 Raianna Fantin,Camila H Coelho The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118 7 Xpert-Ultra for diagnosing asymptomatic tuberculosis Xpert-Ultra用于诊断无症状结核病 Xia Yu,Hairong Huang The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120 8 The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action 基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动 David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122 Correspondence（读者来信） 9 Spillover in dengue trials 登革热试验中的溢出效应 Thomas A Smith,Samuel I Watson The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77 10 Spillover in dengue trials – Author's reply 登革热试验中的溢出效应——作者回复 Fernando Abad-Franch The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78 11 Updating the traditional voriconazole trough concentration range 传统的伏立康唑谷浓度范围更新 Rongqiang Liao,Xiaoyuan Zheng The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79 12 Updating the traditional voriconazole trough concentration range – Authors' reply 传统的伏立康唑谷浓度范围更新——作者回复 Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80 13 Clinical course and neurological profile of Kyasanur Forest disease 基萨努尔森林病的临床病程和神经特征 Nitin Gupta,Tirlangi Praveen Kumar The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82 Corrections（更正） 14 Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7 对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 15 Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4 对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 Newsdesk（新闻台） 16 Promising early data for sorfequiline 索氟维林早期数据令人鼓舞 Ed Holt The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84 17 Highlights from ASTMH 2025 2025年美国热带医学与卫生学会年会亮点 Marco De Ambrogi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85 18 Brazil approves domestic single-shot dengue vaccine 巴西批准国产单剂登革热疫苗 Marcia Triunfol The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86 19 CDC cuts to childhood vaccine recommendations 美国疾控中心削减儿童疫苗接种建议 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87 20 WHO launches unified plan for coronaviruses 世界卫生组织启动冠状病毒统一计划 Talha Burki The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88 21 Infectious disease surveillance update 传染病监测更新 Cahal McQuillan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89 22 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90 Obituary（讣告） 23 Walter Dowdle 沃尔特·道德尔 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124 Profile（人物简介） 24 Katie Anders—improving global dengue control 凯蒂·安德斯——改善全球登革热防控 Tony Kirby The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125 Media Watch（媒体观察） Film（电影） 25 Eliminating Guinea worm 根除麦地那龙线虫 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126 Articles（论著） 26 Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study 奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127 27 Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial 口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验 William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139 28 Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial 头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验 David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148 29 Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验 single-blind, randomised, controlled, dose-ranging, phase 2 trial Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160 30 Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial 人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验 Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170 31 Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study 布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究 Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182 32 Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study 比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究 Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190 33 Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study 乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究 Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203 Review（综述） 34 Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge 侵袭性A组链球菌感染：从2022-23年激增中吸取的教训 Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91 35 A clinical practice guideline for tuberculous meningitis 结核性脑膜炎临床实践指南 Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96 36 Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults 缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症 Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112 Personal View（个人观点） 37 A transformation in cholera surveillance 霍乱监测的变革 Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124 Clinical Picture（临床图像） 38 Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing 尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展 Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130 THE LANCET Infectious Diseases. Volume 26Number 3 柳叶刀传染病学 26卷 3期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL（社论） 1 Promises and challenges of AI in infectious diseases 人工智能在传染病领域的承诺与挑战 The Lancet Infectious Diseases The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213 COMMENT（述评） 2 More real-world evidence for RSV vaccines in the global community 全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据 Kristina L Bajema,Wesley H Self The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214 3 Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet 猴痘快速诊断抗原检测及分散检测的必要性——尚待完善 Daniel Mukadi-Bamuleka,Kevin K Ariën The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215 4 Solving the data bottleneck for artificial intelligence in infectious diseases 解决传染病人工智能领域的数据瓶颈问题 Cesar de la Fuente-Nunez The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217 5 Artificial intelligence and One Health: potential for spillover prediction? 人工智能与“同一健康”理念：能否预测病原体外溢？ Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219 6 Artificial intelligence in the development of vaccines for infectious diseases 人工智能在传染病疫苗研发中的应用 Steve Black,Shabir A Madhi,Rino Rappuoli The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221 7 Peer review at The Lancet Infectious Diseases in 2025 2025年《柳叶刀-传染病学》期刊专家评审 Ursula Hofer The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223 8 Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025 感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家 The Lancet Infectious Diseases Editors The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132 CORRESPONDENCE（读者来信） 9 Methodological considerations in the attribution of long COVID to first or second infection 首次或二次感染导致长期新冠症状的方法学考量 Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139 10 Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply 首次或二次感染导致长期新冠症状的方法学考量——作者回复 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141 11 Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答 Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142 12 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者 Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144 13 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复 David L Paterson,Abdullah T Aslan,Patrick N A Harris The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145 CORRECTIONS（更正） 14 Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0 《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0 The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 15 Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X 《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 NEWSDESK（新闻台） 16 Rabies an increasing threat in Ukraine 乌克兰狂犬病威胁日益加剧 Ed Holt The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147 17 People needing trachoma interventions at record low 需要沙眼干预措施的人数创历史新低 Timothy Jesudason The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148 18 Uneven STI response in EU/EEA countries 欧盟/欧洲经济区国家性传播感染应对措施不均衡 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149 19 Controversial HBV vaccine trial in Guinea-Bissau halted 几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停 Talha Burki The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150 20 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151 OBITUARY（讣告） 21 Ivan Hirsch 伊万·赫希 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224 PROFILE（人物介绍） 22 Reem Abu Shomar— championing water safety in Gaza 里姆·阿布·舒马尔——加沙地带水安全倡导者 Tony Kirby The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225 MEDIA WATCH（媒体观察） Book（书籍） 23 A prescription for public health literacy 提升公众健康素养的良方 Vijay Shankar Balakrishnan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226 Book（书籍） 24 Imagining the inevitable 想象不可避免之事 Cahal McQuillan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227 Film（电影） 25 Women's autonomy, safe sex and HIV prevention 女性自主权、安全性行为与艾滋病预防 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228 ARTICLES（论著） 26 Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study 英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究 Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229 27 Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial 印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验 Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239 28 Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial 血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析 Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250 29 Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study 刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究 Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260 30 Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis 伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析 Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270 31 Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析 GBD 2023 Chagas Disease and RAISE Study Collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284 32 Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial 乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验 Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302 33 Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial 美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验 Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314 SERIES（研讨会） Artificial Intelligence and Infectious Diseases 人工智能与传染病 34 Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice 人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架 Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152 35 Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives 人工智能与传染病诊断：现状与未来展望 Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168 36 Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery 人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现 Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181 REVIEW（综述） 37 Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia 血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议 Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193 CLINICAL PICTURE（临床图像） 38 Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection 人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染 Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B Spiller,Baharak Afshar The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207 THE LANCET Infectious Diseases. Volume 26Number 4 柳叶刀传染病学 26卷 4期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 GoGoVax dispels hopes for gonorrhoea vaccination GoGoVax让淋病疫苗的希望破灭 The Lancet Infectious Diseases The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p329 COMMENT（述评） 2 Do the benefits of universal screening outweigh the harms? 全民筛查的益处是否大于害处？ Alanna N Gillespie,Emma Webb,Valerie Sung The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p330 3 Chikungunya in Brazil: vaccination strategies informed by mathematical modelling 巴西基孔肯雅热：基于数学建模的疫苗接种策略 José Lourenço,Marta Giovanetti The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p331 4 Chikungunya adolescent vaccination and the distinct risk–benefit landscapes 青少年接种基孔肯雅热疫苗及独特的风险-获益情况 Ernesto T A Marques,Simon Barratt-Boyes The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p333 5 Circulation of clade Ib mpox outside of Africa—are we prepared? 非洲以外地区Ib分支猴痘的传播——我们准备好了吗？ Seth D Judson,Claude Kwe Yinda,Franziska K Kaiser,Daniel S Chertow,Emmie de Wit,James O Lloyd-Smith,Vincent J Munster The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p334 6 I worked at WHO: the USA leaving will not make America healthier 我曾在世卫组织工作：美国退出不会让美国更健康 Krutika Kuppalli The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p336 CORRESPONDENCE（读者来信） 7 Maternal views on RSV vaccination in the UK's second season 英国第二季呼吸道合胞病毒疫苗接种的产妇观点 Shaun O'Hagan,Steve Cunningham,Simon B Drysdale,Helen E Groves,Samantha Hunt,Dalia Iskander,Xinxue Liu,Mark D Lyttle,Chengetai D Mpamhanga,Thomas Waterfield,Thomas C Williams,Robin Marlow,Damian Rolandon behalf of the PERUKI & BronchStart/Stop Collaboration The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e209 8 Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters 利用COVID-19 LP.8.1 mRNA加强针克服免疫印记 Ninaad Lasrado,Annika Rössler,Katherine Molloy,Isabella McConnell,Ritobhas Bhowmik,Francisco Armando Granados-Contreras,Jessica Wu,Alejandra Waller-Pulido,Samuel J Nangle,Erica Borducchi,Ai-ris Y Collier,Dan H Barouch The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e212 CORRECTIONS（更正） 9 Correction to Lancet Infect Dis 2025; published online Nov 27. https://doi.org/10.1016/S1473-3099(25)00605-X 《柳叶刀-传染病学》2025年刊载内容更正；在线发布于11月27日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 10 Correction to Lancet Infect Dis 2026; 26: 343–61 《柳叶刀-传染病学》2026年刊载内容更正；26卷：343-61页 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 11 Correction to Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3 《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月23日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 12 Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9 《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月28日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 NEWSDESK（新闻台） 13 UK loses measles elimination status as cases rise 随着病例增加，英国失去麻疹消除地位 Priya Venkatesan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e215 14 Brazil launches implementation study of lenacapavir 巴西启动来那卡帕韦实施研究 Tony Kirby The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e216 15 Clade Ib mpox in southwest Indian Ocean islands 西南印度洋岛屿出现Ib分支猴痘 Esther Nakkazi The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e217 16 EMA approves combined COVID-19 and flu mRNA vaccine 欧洲药品管理局批准COVID-19和流感联合mRNA疫苗 Talha Burki The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e218 17 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e219 OBITUARY（讣告） 18 Nicholas John White 尼古拉斯·约翰·怀特 Sanjeet Bagcchi The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p339 PROFILE（人物简介） 19 Katharina Kranzer—led by curiosity, committed to capacity 卡塔琳娜·克兰泽——受好奇心驱使，致力于提升能力 Tony Kirby The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p340 MEDIA WATCH（媒体观察） Film（电影） 20 Leishmaniasis: a story of two continents 利什曼病：两个大陆的故事 Vijay Shankar Balakrishnan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p341 Book（书籍） 21 Finding your voice in a world of uncertainty 在不确定的世界中找到自己的声音 Carrie Fielden The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p342 ARTICLES（论著） 22 Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1990-2023年下呼吸道感染的全球负担及病因：2023年全球疾病负担研究的系统分析 GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators GBD 2023下呼吸道感染和抗菌素耐药性协作组 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p343 23 Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis 英国苏格兰地区母体RSVpreF疫苗对婴儿严重疾病的保护效果：一项全国性、基于人群的病例对照研究和队列分析 Isobel McLachlan,Chris Robertson,Kirsty E Morrison,Ross McQueenie,Safraj Shahul Hameed,Cheryl Gibbons,Rachael Wood,Rachel Merrick,Louisa Pollock,Antonia Ho,Ting Shi,Thomas C Williams,Sir Aziz Sheikh,Jim McMenamin,Sam Ghebrehewet,Kimberly Marsh The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p362 24 Post-COVID-19 resurgence of Mycoplasma pneumoniae infections in French children (ORIGAMI): a retrospective and prospective multicentre cohort study 法国儿童COVID-19后支原体肺炎感染的复现（ORIGAMI）：一项回顾性和前瞻性多中心队列研究 Anaïs Chosidow,Zoha Maakaroun-Vermesse,Vichita Ok,Cécile Delecroix,Pascal Le Roux,Marie-Aliette Dommergues,Justine de Larminat,Eric Jeziorski,Pauline Ronjat,Léa Jaume,Anne Welfringer-Morin,Cécile Bébéar,Maud Gits-Muselli,Delphine Viriot,Charles-Joris Roux,Stéphane Bechet,Anne-Sophie Romain,Mathie Lorrot,Robert Cohen,Corinne Levy,Jérémie F Cohenon behalf of the ORIGAMI Study Group The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p374 25 Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study 以色列先天性巨细胞病毒筛查项目的3年经验教训：一项前瞻性基于人群的队列研究 Smadar Eventov Friedman,Noa Ofek Shlomai,Esther Oiknine-Djian,Tal Sido,Oren Gordon,Sraya Greenberger,Hadar Horowitz,Lior Merav,Stav David Mehaber,Orit Caplan,Miriam Geal-Dor,Natalia Simanovsky,Diana Averbuch,Colin Kunzweiler,Yosefa Hefter,John Diaz-Decaro,Ora Paltiel,Moran Yassour,Dana G Wolf The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p384 26 Comparison of the performance and costs of testing algorithms using rapid diagnostic tests for detection and treatment of syphilis among pregnant individuals and men who have sex with men: a modelling study 使用快速诊断检测方法对孕妇和男男性行为者进行梅毒检测和治疗的不同检测算法的性能和成本比较：一项建模研究 Ying Zhang,Eric P F Chow,Lei Zhang,Christopher K Fairley,Jason J Ong The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p394 27 The epidemiology of chikungunya virus in Brazil and the potential impact of vaccines: a mathematical modelling study 巴西基孔肯雅热病毒的流行病学及疫苗的潜在影响：一项数学建模研究 Oscar Cortes-Azuero,Megan O'Driscoll,Gabriel Ribeiro dos Santos,Ronaldo de Jesus,Shirlene T S de Lima,Danny Scarponi,Christinah Mukandavire,Arminder Deol,Moritz U G Kraemer,William M de Souza,Henrik Salje The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p406 28 Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil 青少年接种减毒活基孔肯雅热病毒疫苗的安全性和免疫原性：巴西流行地区一项为期12个月、双盲、随机、安慰剂对照的3期试验最终结果 Vera Buerger,Andrea Pfeiffer,Petra Schoengrundner,Jutta Seebacher,Romana Hochreiter,Karin Kosulin,Oliver Zoihsl,Petronela Weisova,Robert Mader,Ana Paula Loch,Eolo Morandi Jr,Mauricio Lacerda Nogueira,Carlos Alexandre Antunes de Brito,Julio Croda,Mauro Martins Teixeira,Ivo Castelo-Branco Coelho,Ricardo Gurgel,Allex Jardim da Fonseca,Marcus Vinícius Guimarães de Lacerda,Edson Duarte Moreira Jr,Ana Paula Rocha Veiga,Susanne Eder-Lingelbach,Juan Carlos Jaramillo The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p417 29 National burden of and optimal vaccine policy for Japanese encephalitis virus in Bangladesh: a seroprevalence and modelling study 孟加拉国日本脑炎病毒的全国负担及最佳疫苗接种政策：一项血清流行率和建模研究 Mariana Perez Duque,Kishor K Paul,Rebeca Sultana,Gabriel Ribeiro dos Santos,Megan O'Driscoll,Abu M Naser,Mahmudur Rahman,Mohammad Shafiul Alam,Hasan M Al-Amin,Mohammed Z Rahman,Mohammad E Hossain,Repon C Paul,Elias Krainski,Stephen P Luby,Simon Cauchemez,Jessica Vanhomwegen,Emily S Gurley,Henrik Salje The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p429 REVIEW（综述） 30 Autoantibodies in long COVID: a systematic review 长新冠中的自身抗体：一项系统综述 Fabian Wilhelm,Janne Cadamuro,Sylvia Mink The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e220 31 Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE) 登革热临床试验核心结局测量指标集：一项国际德尔菲共识研究（DEN-CORE） Sophie Yacoub,Anastasia Demidova,Xin Hui S Chan,Ali Ajam,Dina Baimukhambetova,Andreij Horn,Evgeniia Kakotkina,Mark Kosenko,Aigun Mursalova,Jennifer Ilo Van Nuil,Chi Le Phuong,Lin Xiao,Sudeep Adhikari,Juan David Alzate Alvarez,Kathryn B Anderson,Panisadee Avirutnan,Stephanie Buchholz,Richa Chandra,Aileen Y Chang,Ho Quang Chanh,Mónika Patricia Consuegra Rodríguez,Vanessa Daniel,Janet V Diaz,Claudia Figueiredo-Mello,Rosa Margarita Gelvez-Ramírez,Tran Bang Huyen,Evelyne Kestelyn,Phung Khanh Lam,Stije J Leopold,Ruobing Li,Tran Luu,David Chien Boon Lye,Angela McBride,Isabelle Meyer-Andrieux,Nathaniel J Moorman,Nguyet Minh Nguyen,Sharifah Faridah Syed Omar,Hang Cheng Ong,Eng Eong Ooi,Ekaterina Pazukhina,Sarah L Pett,Diego Bastos Porto,Giri S Rajahram,Marc Rogers,Elsa Rojas,James Rosen,Jamie Rylance,William H K Schilling,Andre M Siqueira,Peter Sjö,Alfonso Sucerquia-Hernandez,Dong Thi Hoai Tam,Mauro Martins Teixeira,Andreas Tietz,Huynh Trung Trieu,Annalise Unsworth,Luis Villar,Adam Tully Waickman,James A Watson,Bridget A Wills,Po Ying Chia,Patricia Brasil,Thomas Jaenisch,Lucy Lum,Gathsaurie Neelika Malavige,Steven McGloughlin,Bharath Kumar Tirupakuzhi Vijayaraghavan,Laura Merson,Daniel Munblitthe DEN-CORE Study Group The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e231 PERSONAL VIEW（个人观点） 32 Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali 通过国家层面整合社区监测和响应，打破低收入和中等收入国家人畜共患病报告不足的循环：来自喀麦隆、乍得、科特迪瓦和马里的见解 Katherine E L Worsley-Tonks,Mahamat Fayiz Abakar,Zanan Coulibaly,Marie Paulette Deya-Yang,Linda Esso,Jean Marc Kameni Feussom,Vessaly Kallo,Zakaria Keita,Monique Lechenne,Magloire Tchamba Kombou,Inès Emah Manda,Christiane Mangou,Stephanie Mauti,Aime Gilert Mbonda Noula,Rodrigue Poueme Namegni,Perrine Parize,Mathurin Cyrille Tejiokem,Isaac Tiembre,Abdallah Traoré,Jakob Zinsstag,Hervé Bourhy The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e245 GRAND ROUND（大查房） 33 Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned 儿童侵袭性A组链球菌坏死性肌炎病例：诊断挑战和经验教训 Suraya Yusuf,Michael James Carter,Jenny Woodruff,Peter Kalu,Justin Conrad Rosen Wormald,Claire Sethu The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e259 CLINICAL PICTURE（临床图像） 34 Bullous haemorrhagic cellulitis caused by Escherichia coli in a patient with cirrhosis 肝硬化患者由大肠杆菌引起的大疱性出血性蜂窝织炎 Irene Rivera-Ruiz,Paloma Elma Alañón-Martínez,Elisa Vidal-Verdú The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e268

2026-03-23

·卫泰牧业

小分子抗病毒药物抑制剂研究进展

摘要病毒感染性疾病始终是威胁人类健康、畜禽养殖产业安全的全球性难题，传统疫苗、抗生素在应对高变异RNA病毒、新发突发疫病、耐药毒株时存在明显局限性。小分子抗病毒抑制剂凭借分子量小、组织穿透性强、给药便捷、靶点精准、易于工业化生产等独特优势，成为抗病毒药物研发的核心赛道。本文系统阐述小分子抗病毒抑制剂的作用机理，聚焦猫传染性腹膜炎、猪繁殖与呼吸综合征（蓝耳病）、猪流行性腹泻病毒、非洲猪瘟、流感病毒等重点领域，梳理国内外核心期刊、权威机构发布的最新研究成果与临床应用现状，分析当前研发与产业化面临的瓶颈，结合宠物医疗、生猪养殖、人类公共卫生等实际生产生活场景，展望小分子抗病毒药物的未来发展方向与应用前景，为跨领域抗病毒药物研发、疫病防控策略优化提供理论参考与数据支撑。关键词小分子抑制剂；抗病毒机理；猫传腹；蓝耳病毒；腹泻病毒；非洲猪瘟；流感病毒；研究进展；产业化应用一、引言病毒是一类无细胞结构的寄生性微生物，必须借助宿主细胞的代谢系统完成复制、增殖与传播，其高突变率、跨物种传播能力、免疫逃逸特性，使得抗病毒防控难度持续攀升。人类临床中，流感病毒每年引发季节性流行，新发冠状病毒反复造成公共卫生危机；畜禽养殖领域，蓝耳病、非洲猪瘟、流行性腹泻等疫病爆发导致巨额经济损失，严重冲击产业链稳定；伴侣动物医疗方面，猫传染性腹膜炎曾因致死率极高被称为“宠物绝症”，长期缺乏有效治疗手段。传统抗病毒手段中，疫苗依赖病毒抗原稳定性，对高变异毒株保护效力不足，且研发周期长，难以应对突发疫情；抗生素仅针对细菌感染，对病毒完全无效；中和抗体等生物制剂生产成本高、给药不便、组织穿透性弱，限制了规模化应用。相比之下，小分子抗病毒抑制剂可直接靶向病毒复制关键环节或宿主依赖因子，快速阻断病毒增殖，兼具治疗与预防双重潜力，且结构可修饰性强、药代动力学易优化，适配临床治疗、养殖场防控、家庭常备等多元场景。近年来，随着结构生物学、计算机辅助药物设计、高通量筛选技术的飞速发展，小分子抗病毒抑制剂研发取得突破性进展，多款药物实现临床转化与产业落地。本文基于《Journal of Virology》《Virologica Sinica》《中国农业科学》等国内外核心期刊，以及中国农业科学院、美国FDA、欧洲药品管理局等权威机构发布的研究数据，全面剖析小分子抗病毒药物的机理、应用、现状与未来，为相关领域科研攻关、实际应用提供系统性参考。二、小分子抗病毒抑制剂核心作用机理小分子抗病毒抑制剂的作用本质是通过特异性结合靶点蛋白、干扰病毒核酸合成、调控宿主细胞通路等方式，阻断病毒生命周期的关键步骤，从而抑制病毒感染、复制、组装与释放，达到抗病毒效果。根据作用靶点与干预环节，可分为直接靶向病毒因子和靶向宿主依赖因子两大类，两类机制各具优势，协同提升抗病毒效力。2.1 直接靶向病毒因子的抑制机理直接靶向病毒自身蛋白、核酸等关键因子，特异性强、对宿主细胞毒性低，是小分子抗病毒药物研发的主流方向，核心作用靶点包括病毒蛋白酶、RNA依赖的RNA聚合酶（RdRp）、刺突蛋白（S蛋白）、衣壳蛋白等。2.1.1 病毒蛋白酶抑制剂多数RNA病毒在复制过程中会合成多聚蛋白前体，需经蛋白酶切割裂解为具有功能活性的成熟蛋白，才能完成后续复制与组装。3C样蛋白酶（3CLpro）、木瓜样蛋白酶（PLpro）是冠状病毒、腹泻病毒等的核心蛋白酶，也是小分子抑制剂的黄金靶点。这类抑制剂通过模拟底物结构，与蛋白酶活性位点共价或非共价结合，占据底物结合口袋，阻断蛋白酶对多聚蛋白的切割，使病毒无法合成功能性蛋白，彻底终止复制进程。例如猫传腹病毒抑制剂GC376、新冠病毒抑制剂奈玛特韦，均通过靶向3CLpro发挥强效抗病毒作用。2.1.2 RNA依赖的RNA聚合酶（RdRp）抑制剂 RdRp是RNA病毒复制的核心酶，负责催化病毒基因组RNA的合成，是所有RNA病毒共有的保守靶点，耐药风险相对较低。该类抑制剂主要分为核苷类似物与非核苷类似物：核苷类似物可掺入病毒RNA链，导致链终止或致死性突变，使病毒失去复制能力，如瑞德西韦活性代谢物GS-441524、法匹拉韦；非核苷类似物则通过结合RdRp的变构位点，改变酶的空间构象，抑制其催化活性，兼具广谱抗病毒潜力。2.1.3 病毒入侵与释放抑制剂病毒通过刺突蛋白与宿主细胞受体结合、膜融合完成入侵，通过神经氨酸酶等完成子代病毒释放。这类小分子抑制剂可阻断S蛋白与受体结合、抑制膜融合过程，或阻断神经氨酸酶活性，阻止子代病毒释放扩散。例如流感病毒神经氨酸酶抑制剂奥司他韦、玛舒拉沙韦，以及靶向猪流行性腹泻病毒S1蛋白的丹参酚酸A，均通过干预病毒入侵或释放环节发挥作用。2.2 靶向宿主依赖因子的抑制机理病毒复制高度依赖宿主细胞的信号通路、代谢途径、蛋白因子，靶向宿主因子的抑制剂不易受病毒突变影响，耐药性风险极低，且具备广谱抗病毒潜力。核心机制是调控宿主细胞内与病毒复制相关的激酶、热休克蛋白、钙通道、免疫通路等，切断病毒复制的“宿主支撑系统”，同时减轻病毒引发的炎症损伤，实现抗病毒与抗炎双重功效。例如，靶向宿主热休克蛋白HSP90的抑制剂PS10，可降解蓝耳病毒复制必需的非结构蛋白，广谱抑制不同基因型蓝耳毒株；靶向钙通道Cav1.2的地尔硫卓，可阻断猪流行性腹泻病毒的吸附与内化过程；靶向PI3K/Akt通路的抑制剂，可抑制非洲猪瘟病毒复制并缓解炎症因子风暴。这类抑制剂虽存在潜在宿主毒性，但通过结构优化、剂量调控，可实现安全性与有效性的平衡。2.3 联合抑制机理为应对病毒高变异特性、延缓耐药性产生、提升抗病毒效力，临床与科研中常采用双靶点/多靶点联合抑制策略，即同时靶向病毒因子与宿主因子，或靶向病毒生命周期多个环节，发挥协同增效作用。例如猫传腹治疗中采用GC376（3CLpro抑制剂）与GS-441524（RdRp抑制剂）联用，可缩短疗程、提升治愈率；流感治疗中采用聚合酶抑制剂与神经氨酸酶抑制剂联用，对耐药毒株仍保持高效力。三、重点领域小分子抗病毒抑制剂研究与应用进展3.1 猫传染性腹膜炎（FIP）小分子抑制剂研究进展猫传染性腹膜炎是由猫冠状病毒（FIPV）突变引发的高致死性伴侣动物疫病，分为湿性、干性、神经眼型三大类，传统对症治疗治愈率不足5%。近年来，小分子抗病毒抑制剂的研发彻底改写了FIP无药可治的局面，成为宠物医疗领域的里程碑突破，相关研究成果发表于《Journal of Feline Medicine and Surgery》《Veterinary Microbiology》等核心期刊。3.1.1 核心药物研发与临床效果 GC376：全球首款针对猫传腹的3CLpro小分子抑制剂，由美国堪萨斯州立大学研发，可强效阻断FIPV多聚蛋白切割，体外抑制活性IC50达纳摩尔级。临床试验显示，GC376对湿性FIP效果显著，12周规范疗程下，临床症状缓解率超85%，患猫腹水消退、食欲恢复、炎症指标显著改善；但该药存在脑脊液穿透性差、对神经型FIP效力不足、需注射给药等短板，单独使用易复发。 GS-441524：瑞德西韦的活性代谢产物，属于RdRp抑制剂，具备极强的组织穿透性，脑脊液、房水浓度可达血浆浓度的21.4%，完美弥补GC376的缺陷。针对31例湿性FIP患猫的临床试验表明，12周疗程存活率达83.8%，对神经型、眼型FIP治愈率超70%；口服制剂研发成功后，大幅提升了给药依从性，降低了宠物主人的护理难度。3.1.2 联合用药与前沿进展临床中采用GC376与GS-441524联合给药，可发挥协同抗病毒作用，将疗程从12周缩短至4周，46例不同类型FIP患猫治疗后，长期存活率达97.8%，复发率降至5%以下。此外，亲环蛋白抑制剂F83233、广谱冠状病毒抑制剂Pocapavir等前沿药物，已进入临床前研究阶段，具备跨物种抑制FIPV、PEDV等多种病毒的潜力，有望实现一针多防的效果。3.1.3 实际应用与产业现状目前，GS-441524与GC376已成为全球宠物医院治疗FIP的金标准方案，商业化制剂逐步规范化，价格趋于亲民，让众多患病猫咪得到救治。但仍存在药物纯度参差不齐、非法制剂泛滥、神经型FIP治疗周期长等问题，亟需完善兽用药物审批与质量监管体系。3.2 猪繁殖与呼吸综合征（蓝耳病，PRRSV）小分子抑制剂研究进展蓝耳病是危害全球生猪养殖产业的头号疫病，由PRRSV引起，该病具有高变异、高免疫抑制、垂直传播等特性，传统疫苗保护率不足60%，且易引发病毒重组变异，养殖场防控压力极大。小分子抑制剂作为疫苗的补位手段，成为蓝耳病防控的新方向，相关研究集中于中国农业科学院、华中农业大学等权威机构，成果发表于《Veterinary Microbiology》《中国兽医学报》等期刊。3.2.1 靶向病毒因子的抑制剂 PRRSV RdRp、Nsp2、Nsp3等非结构蛋白是核心靶点，多款小分子抑制剂展现出优异的体外活性。例如，化合物C14可同时靶向PRRSV RdRp与CD163受体，对经典株、高致病性株的EC50低至0.34μM，抑制率超90%；硝唑尼特（NTZ）通过抑制病毒内化与复制，可降低仔猪体内病毒载量2-3个对数级，缓解肺部炎症损伤。3.2.2 靶向宿主因子的抑制剂宿主HSP90、PI3K/Akt、自噬通路是蓝耳病毒复制的关键依赖，相关抑制剂兼具抗病毒与抗炎功效。PS10（HSP90抑制剂）可下调宿主HSP90表达，降解PRRSV多种非结构蛋白，广谱抑制1型、2型蓝耳毒株，同时降低IL-6、TNF-α等炎症因子水平，减轻免疫损伤；白藜芦醇、槲皮素等天然小分子抑制剂，通过调控自噬与铁死亡通路，缩短仔猪康复周期42%，安全性高、成本低廉，适配规模化猪场应用。3.2.3 实际生产应用现状目前，蓝耳病小分子抑制剂仍以临床前研究与田间试验为主，部分天然产物提取物、老药新用制剂已在养殖场试点应用，用于蓝耳病爆发后的紧急防控与母猪保健。但兽用专用制剂审批滞后、大规模给药方案不完善、耐药毒株风险等问题，制约了其产业化落地，未来需聚焦口服缓释制剂、复方制剂研发，适配猪场饮水、拌料给药模式。3.3 猪流行性腹泻病毒（PEDV）小分子抑制剂研究进展猪流行性腹泻是由PEDV引起的急性接触性肠道传染病，新生仔猪死亡率接近100%，给生猪养殖造成毁灭性损失。PEDV变异速度快，传统疫苗保护效力持续下降，小分子抑制剂凭借肠道靶向性强、起效快等优势，成为防控仔猪腹泻的新利器，相关研究成果收录于《Journal of Virological Methods》《畜牧兽医学报》。3.3.1 核心抑制剂研发成果丹参酚酸A（SalA）：靶向PEDV S1受体结合域，阻断病毒与肠道上皮细胞结合，仔猪动物模型中，可将腹泻率从100%降至33%，提升肠绒毛高度60%，修复肠道黏膜损伤，病毒载量下降1-2个对数级，安全窗宽、无残留，适合仔猪保健。氯法齐明（CFZ）：双靶向S蛋白与RdRp，体外IC50仅0.1364μM，与瑞德西韦联用具有协同增效作用，可彻底阻断病毒入侵与复制；根皮素衍生物A12靶向3CLpro保守位点，广谱抑制PEDV、TGEV、PDCoV等多种腹泻病毒，活性提升15.7倍，适配猪场多毒株混合感染防控。地尔硫卓：老药新用典范，通过阻断宿主Cav1.2钙通道，抑制PEDV吸附与内化过程，生产成本低、药效稳定，适合规模化猪场紧急预防给药。3.3.2 养殖场景应用优势 PEDV小分子抑制剂可通过拌料、饮水、灌服等方式给药，起效快、肠道浓度高，既能用于仔猪发病后的治疗，也可用于母猪产前保健，阻断垂直传播。天然小分子抑制剂无休药期、无耐药性，契合养殖业减抗禁抗政策，未来可与益生菌、肠道修复剂联用，构建“抗病毒+护肠道”的综合防控方案。3.4 非洲猪瘟（ASFV）小分子抑制剂研究进展非洲猪瘟是由ASFV引起的烈性传染病，致死率100%，目前全球无商用疫苗与特效药，是生猪养殖产业的“头号杀手”。小分子抑制剂作为应急防控储备药物，成为ASFV防控的研究热点，中国农业科学院兰州兽医研究所、美国农业部等机构开展了大量研究，成果发表于《Virology》《中国农业科学》。3.4.1 核心靶点与抑制剂研发 ASFV S273R蛋白酶、g5Rp蛋白、PI3K/Akt/NF-κB通路是核心研发靶点，多款抑制剂展现出良好的体外抑制活性。防己诺林碱（FAN）通过抑制AKT/mTOR/NF-κB通路，IC50达1.66μM，可降低病毒复制效率，缓解炎症损伤；9-甲基丹参多酚酸盐B靶向g5Rp蛋白，10μM浓度下抑制率达63%，是首个靶向ASFV g5Rp的先导化合物；S273R蛋白酶共价抑制剂，可特异性结合病毒半胱氨酸蛋白酶，纳摩尔级浓度即可阻断病毒多蛋白加工，成为ASFV药物研发的核心方向。3.4.2 广谱抗病毒与应急应用潜力 Brequinar（BQR）等嘧啶合成抑制剂，通过双重阻断ASFV复制与诱导铁死亡，兼具抗DNA、RNA病毒潜力，可用于ASFV与蓝耳病、腹泻病毒混合感染防控；RMC-113等宿主靶向抑制剂，可抑制多种囊膜病毒复制，作为ASFV爆发后的应急储备药物，降低养殖场疫情扩散风险。3.4.3 研发瓶颈与现状目前ASFV小分子抑制剂均处于临床前研究阶段，缺乏体内药效与安全性数据，且ASFV复制周期复杂、宿主范围广，药物筛选难度极大。但随着ASFV结构生物学研究的深入，基于晶体结构的虚拟筛选、AI辅助药物设计加速了先导化合物发现，未来有望突破成药性瓶颈，开发出商用防控制剂。3.5 流感病毒小分子抑制剂研究进展流感病毒是引发人类季节性流感、大流行的核心病原体，每年造成全球数百万人感染，传统疫苗需每年更新，奥司他韦等药物耐药毒株日益增多。小分子聚合酶抑制剂、新型神经氨酸酶抑制剂的研发，实现了流感治疗的跨越式升级，相关成果发表于《Nature Medicine》《New England Journal of Medicine》等顶级期刊。3.5.1 临床成熟药物与应用玛舒拉沙韦/玛硒洛沙韦：中国原创1类抗流感新药，靶向流感病毒PA亚基，单次口服即可起效，症状缓解时间缩短至42小时，耐药率低于1%，覆盖甲、乙型流感及奥司他韦耐药毒株，适合家庭防控、集中隔离场景，已在国内获批上市。昂拉地韦：全球首款PB2亚基抑制剂，阻断病毒mRNA转录，长效抑制耐药毒株，轻症患者口服1-2次即可转阴；ADC189、7j等新型抑制剂，对奥司他韦耐药株活性优异，EC50低至纳摩尔级，细胞毒性更低，破解了传统药物耐药难题。3.5.2 实际生活与公共卫生应用流感小分子抑制剂具备口服便捷、起效快、居家可使用等优势，可有效减少医疗挤兑，降低重症转化率；在学校、养老院、机场等密集场所，可作为暴露后预防药物，阻断疫情传播。同时，广谱流感抑制剂可应对新型流感毒株的突发流行，成为公共卫生应急储备的核心物资。四、小分子抗病毒抑制剂研发与应用现存挑战4.1 病毒耐药性问题突出 RNA病毒突变率极高，单靶点小分子抑制剂长期使用易诱导靶点氨基酸突变，导致药物效力下降甚至失效。例如流感病毒对奥司他韦的耐药率逐年上升，猫传腹病毒长期单用GC376易出现耐药株，蓝耳病、腹泻病毒变异速度快，进一步加剧了耐药风险。4.2 兽用药物审批与产业化滞后畜禽、伴侣动物抗病毒药物研发投入少、审批流程复杂，多数优秀候选药物仅停留在实验室阶段，缺乏规范的临床试验、质量标准与商用制剂；非法制剂、劣质产品充斥市场，不仅药效不佳，还易引发毒副作用、耐药性扩散，制约了行业规范化发展。4.3 药物成药性与安全性短板部分小分子抑制剂存在水溶性差、组织穿透性不足、体内代谢快、细胞毒性高等问题，如GC376脑脊液穿透性弱、部分ASFV抑制剂体内活性远低于体外活性；靶向宿主因子的抑制剂易对正常细胞功能产生影响，需进一步优化结构、降低毒性。4.4 规模化应用成本偏高宠物用小分子抑制剂前期研发成本高，商业化初期价格昂贵，加重饲养者负担；畜禽养殖用药物需兼顾成本与药效，部分高活性合成化合物难以适配大规模给药需求，天然产物提取物存在纯度低、稳定性差等问题。4.5 跨物种传播与新发病毒应对不足针对新发突发病毒、跨物种传播病毒的小分子抑制剂储备不足，药物研发周期远慢于病毒变异与传播速度，缺乏广谱、快速响应的抗病毒药物体系，难以应对未来新发疫病危机。五、小分子抗病毒抑制剂未来发展方向与应用前景5.1 多靶点、广谱抗病毒药物研发聚焦病毒保守靶点（3CLpro、RdRp）与宿主通用通路，开发多靶点、跨物种广谱抑制剂，实现“一药防多毒”。例如同时靶向猫传腹、腹泻病毒的3CLpro抑制剂，兼顾蓝耳病、非瘟的复方制剂，应对流感、冠状病毒的广谱聚合酶抑制剂，大幅提升疫病防控效率。5.2 AI辅助与精准药物设计依托AlphaFold2蛋白质结构预测、分子动力学模拟、虚拟高通量筛选等技术，快速精准识别先导化合物，缩短研发周期、降低成本；结合AI优化药物结构，提升水溶性、组织穿透性与选择性，降低毒副作用，加速药物临床转化。5.3 联合用药与复方制剂开发推广“病毒靶点+宿主靶点”“不同作用机制”联合用药方案，延缓耐药性产生、提升抗病毒效力。例如猫传腹的复方口服制剂、猪场蓝耳+腹泻复方防控药物、流感复方治疗药物，简化给药流程，提升临床依从性。5.4 制剂创新与递送系统优化开发口服缓释、纳米递送、肠道靶向等新型制剂，提升药物生物利用度与组织穿透性；针对畜禽养殖，研发饮水型、拌料型制剂，适配规模化给药；针对宠物医疗，开发适口性强的口服制剂、长效注射剂，降低护理难度。5.5 兽用药物合规化与产业规范化加快完善兽用抗病毒药物审批体系，建立规范的药效评价、质量控制标准，推动FIP、蓝耳病、腹泻病专用药落地；加强市场监管，打击非法制剂，引导产业良性发展，让优质小分子药物惠及更多养殖主体与宠物家庭。5.6 跨界融合与应急储备体系构建推动人用与兽用抗病毒药物双向转化，例如瑞德西韦从人用新冠药物拓展至猫传腹治疗，玛舒拉沙韦从人用流感药物研发畜禽适用剂型；建立小分子抗病毒药物应急储备库，针对高风险病毒提前布局研发，提升突发疫情应对能力。5.7 贴合生产生活的场景化应用在宠物医疗领域，实现FIP等绝症的普惠化治疗，提升伴侣动物福利；在生猪养殖领域，构建“疫苗+小分子抑制剂”综合防控模式，降低疫病损失，保障产业链安全；在人类公共卫生领域，普及居家便捷型抗病毒药物，减少流感等流行病的重症率与传播率，守护全民健康。六、结论小分子抗病毒抑制剂凭借机理清晰、靶点精准、给药便捷、易于产业化等核心优势，在猫传腹、蓝耳病、猪流行性腹泻、非洲猪瘟、流感等疫病防控中展现出不可替代的价值，彻底改写了部分绝症无药可治、传统手段防控失效的局面。从宠物医疗的生命救治，到畜禽养殖的产业保供，再到人类公共卫生的疫情防控，小分子抗病毒药物贯穿生产生活全场景，成为跨领域抗病毒防控的核心支撑。当前，小分子抗病毒抑制剂研发虽面临耐药性、审批滞后、成药性不足等挑战，但随着结构生物学、AI技术、制剂工艺的飞速发展，多靶点设计、联合用药、广谱研发等策略将逐步突破瓶颈。未来，随着药物合规化、产业化、场景化进程加快，小分子抗病毒抑制剂将实现更高效、更安全、更普惠的应用，为全球病毒感染性疾病防控、畜禽产业健康发展、人类生命健康保障提供强有力的技术支撑，开启抗病毒防控的新时代。参考文献（核心来源）刘新泳, 展鹏. Antiviral drug discovery and development: challenges and future directions[J]. Signal Transduction and Targeted Therapy, 2026. 上市小分子抗病毒药物研究进展[J]. 大学化学, 2025. 靶向SARS-CoV-2 RNA抗病毒小分子药物研究进展[J]. 中国药科大学学报, 2025. 猫传染性腹膜炎小分子抑制剂临床研究[J]. Journal of Feline Medicine and Surgery, 2024. 猪蓝耳病小分子抑制剂研发与田间应用[J]. 中国兽医学报, 2025. 非洲猪瘟病毒小分子抑制剂筛选与机制研究[J]. Virology, 2024. 抗流感新型小分子抑制剂临床Ⅲ期数据[J]. New England Journal of Medicine, 2025. 猪流行性腹泻病毒天然小分子抑制剂研究[J]. 畜牧兽医学报, 2024. 广谱抗病毒小分子RMC-113作用机制[J]. Nature Communications, 2025. 中国农业科学院. 畜禽抗病毒小分子药物研发白皮书[R]. 2025.

疫苗

2026-03-22

·结核病研究新进展

【前沿】三大抗结核新药联用安全吗？PK/PD模型揭示QT延长真实风险

面对耐药结核病（DR-TB），多种新药的联合使用带来了希望，但也引发了对心脏毒性的担忧。近期，一项发表在《Antimicrobial Agents and Chemotherapy》上的药代动力学/药效学（PK/PD）建模研究，为我们揭开了三大核心抗结核药物联合使用时的心脏安全密码。 1. 研究背景结核病（Tuberculosis, TB）依然是全球头号感染性杀手，而耐药结核病更是棘手。目前，世界卫生组织推荐的DR-TB治疗方案高度依赖三种药物：bedaquiline (BDQ)、pretomanid (Pa)和clofazimine (CFZ)。这三种药物都有一个共同的副作用：延长心电图的QT间期（可能导致严重心律失常）。然而，当这三种药物“强强联手”时，它们对QT间期的叠加效应究竟如何？目前临床上仍缺乏明确的数据指导。本研究旨在通过数学建模，描述这三种药物的联合暴露-QTc效应，并预测不同给药方案下的心脏毒性风险。 2. 研究方法本研究的数据来自一项针对药物敏感型结核病（DS-TB）患者的为期14天的早期杀菌活性（EBA）二期临床试验。 · 样本规模：纳入105名成人患者，共收集了2,062份心电图（ECG）读数，并与同期的药代动力学（PK）血药浓度数据精准匹配。 · 建模方法：研究团队开发了一个竞争性相互作用模型（Competitive interaction model），将BDQ（通过其主要代谢物BDQM2）、Pa和CFZ的血药浓度与QTcF（经Fridericia公式校正的QT间期）联系起来。模型还考虑了昼夜节律和与药物无关的随时间推移的长期趋势（Secular trend）。 3. 研究结果数据表明，这三种药物在引起QT延长时并不是简单的线性叠加，而是表现出“竞争性拮抗”。也就是说，由于它们可能竞争同一个靶点（如hERG通道），当联合使用时，需要更高的药物浓度才能达到单独使用时的最大延长效果。 · 核心药效参数（Table 2 与 Figure 2）： o模型计算出三种药物联合导致的最大QT增加值（Emax）共享(a shared Emax)为 44.5 毫秒（ms）。 o各自引发一半最大效应的浓度（EC50）分别为：BDQM2 0.57 mg/L，CFZ 0.903 mg/L，Pa 26.9 mg/L。 · 高危人群的模拟预测（Table 3 与 Figure 3）：研究对不同给药方案（如BPaL方案和UNITE4TB项目方案）进行了10万次蒙特卡洛模拟。以高危人群（70岁，非黑人血统，此类人群BDQ清除率低，药物暴露量大）为例： o在BPaL方案的负荷剂量期（8周）结束时，39.1%的模拟患者出现了药物驱动的QTcF基线变化（ΔQTcF）> 30 ms。 o在UNITE4TB BDQ方案负荷期（2周）后，这一比例为29.4%。 · 安全性底线兜底：令人欣慰的是，在所有的模拟中，没有任何情况导致绝对QTcF超过极度危险的 500 ms。且不到1%的模拟结果超过了480 ms的绝对值，或基线变化（ΔQTcF）超过60 ms。 4. 研究结论 BDQ、Pa和CFZ联合使用时，会导致非加和性的QT间期延长。该竞争性相互作用模型能够有效预测这些药物在不同给药方案下的QT延长风险。对于高龄且非黑人血统的患者，由于其BDQ暴露量较高，发生具有临床意义的QT延长（ΔQTcF > 30 ms）的风险确实更大，但引发致命性极度延长的可能性极低。 5. 不足之处 · 观察期较短：试验仅持续14-28天，无法评估长期用药可能产生的耐受性。 · 缺乏单药对照：研究中没有BDQ单药治疗组，这使得对BDQM2单独效应的评估不够完美（尽管结果与既往文献相符）。 · 长期趋势（Secular trend）参数的估算存在较大的不确定性。 6. 影响及借鉴意义这项研究为结核病领域的临床医生和新药研发人员提供了一个极具价值的预测工具。它告诉我们：联合使用多种会导致QT延长的抗结核新药是相对安全的，不必因噎废食。但在临床实践中，必须“抓重点”——在治疗初期（负荷剂量期），针对高龄、特定种族等高暴露风险人群，实施更频密的心电图监测，即可有效保障用药安全。 Abdelwahab MT, Svensson EM, Diacon AH, Conradie A, Olugbosi M, Dawson R, Maartens G, Denti P. Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis. Antimicrob Agents Chemother. 2026 Mar 9:e0139925. 更多资讯： 1. 结核病-治疗篇 2. 结核病-实验室诊断篇 3. 结核病-公共卫生篇 4. 结核病-基础研究篇 5. 结核病-NTM及其他 6. 科研门诊备注：本公众号所发布的文章内容来源于互联网公开资料，经过翻译、整理与提炼，仅供读者参考和学习使用。所有原始内容的版权归原作者及相关权利人所有。本公众号不对任何转载内容的版权负责，若涉及侵权，请及时联系我们，我们将在第一时间进行删除处理。欢迎关注、点赞、及分享！也欢迎转发或转载。此外，本公众号对所发布的文章“不具有也不保留”版权。

临床2期临床结果

100 项与氯法齐明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00278	氯法齐明	J04BA01	DB00845

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
麻风	美国	Novartis Pharmaceuticals Corp.	1986-12-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非结核分枝杆菌感染	临床3期	美国	MannKind Corp.	2024-09-11
非结核分枝杆菌感染	临床3期	日本	MannKind Corp.	2024-09-11
非结核分枝杆菌感染	临床3期	澳大利亚	MannKind Corp.	2024-09-11
非结核分枝杆菌感染	临床3期	韩国	MannKind Corp.	2024-09-11
非结核分枝杆菌感染	临床3期	中国台湾	MannKind Corp.	2024-09-11
多重耐药性肺结核	临床3期	立陶宛	Novartis Pharma Services AG	2016-02-11
耐多药结核病	临床3期	立陶宛	Novartis Pharma Services AG	2016-02-11
肺部疾病	临床申请批准	日本	MannKind Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04311502 (Clo-Fast, CTgov)	临床2期	结核 \| 肺结核 \| HIV感染	104	Ethambutol+Rifapentine+Clofazimine loading dose+Isoniazid+Pyrazinamide (Arm 1: Experimental)	窪繭艱範衊構範簾鬱艱(構簾範遞構齋鏇願鹹選) = 鏇簾願範淵衊廠遞繭醖衊獵夢艱餘廠網淵艱廠 (鏇遞鹹窪範襯繭膚選廠, 鏇鑰衊蓋窪齋鹹齋獵構 ~ 廠遞窪觸窪糧製製獵衊) 更多	-	2025-08-27
				Ethambutol+Rifampicin+Isoniazid+Pyrazinamide (Arm 2: Standard of Care)	窪繭艱範衊構範簾鬱艱(構簾範遞構齋鏇願鹹選) = 蓋鑰繭糧醖餘艱築廠膚衊獵夢艱餘廠網淵艱廠 (鏇遞鹹窪範襯繭膚選廠, 憲廠醖醖簾糧簾鬱簾齋 ~ 鑰遞襯膚繭築淵淵築衊) 更多
ERS2024	N/A	-	58	bedaquiline+delamanid+clofazimine+pyrazinamide (24-36 weeks)	網壓衊蓋築餘蓋願憲積(範齋鬱糧鏇築襯築遞鏇) = 淵繭鬱醖餘鹽鑰夢蓋憲鏇齋淵廠艱艱壓積鬱構 (築範築網簾顧鬱願醖積 ) 更多	积极	2024-09-07
				18-20 months WHO-recommended regimen	網壓衊蓋築餘蓋願憲積(範齋鬱糧鏇築襯築遞鏇) = 鬱繭醖築淵鹽糧範範製鏇齋淵廠艱艱壓積鬱構 (築範築網簾顧鬱願醖積 ) 更多
NCT02589782 (TB-PRACTECAL, Pubmed) 人工标引	临床2/3期	广泛耐药结核病	552	rifampicin (Standard care)	願積願顧繭製糧獵蓋艱(網鑰醖鬱壓窪衊積獵鑰) = 餘製齋餘鑰夢觸醖醖鏇顧製鏇網憲淵鹽壓簾網 (壓淵廠廠窪鑰齋範醖範 ) 更多	积极	2024-02-01
				rifampbedaquilinepretomanidlinezolidmoxifloxacin (BPaLM)	願積願顧繭製糧獵蓋艱(網鑰醖鬱壓窪衊積獵鑰) = 憲獵簾憲選構選襯獵獵顧製鏇網憲淵鹽壓簾網 (壓淵廠廠窪鑰齋範醖範 ) 更多
NCT03896685 (endTB-Q, Pubmed)	临床3期	耐多药结核病	324	Bedaquiline, Linezolid, Clofazimine, Delamanid	齋鬱蓋網觸壓壓簾簾膚(壓夢艱鬱糧襯觸鬱壓艱) = 膚顧築襯鑰淵衊齋顧獵築膚膚糧鏇觸選糧構鹽 (網願鹹鑰衊顧窪襯鹽構 )	积极	2023-11-30
				Contemporaneous WHO standard of care for pre-XDR TB	齋鬱蓋網觸壓壓簾簾膚(壓夢艱鬱糧襯觸鬱壓艱) = 蓋夢網膚夢簾衊選築簾築膚膚糧鏇觸選糧構鹽 (網願鹹鑰衊顧窪襯鹽構 )
ERS2023	N/A	-	250	bedaquiline+levofloxacin+linezolid+clofazimine+cycloserine/delamanid	觸鏇選鑰憲觸鹽簾餘築(繭憲襯獵網齋鏇鹽網膚) = 艱憲壓糧網襯鬱繭網鑰襯襯範簾構憲憲選窪遞 (簾憲糧遞淵餘襯觸鏇齋, 1.4 ~ 2.6)	积极	2023-09-09
ERS2023	N/A	耐多药结核病	53	Kanamycin+Pyrazinamide+Ethambutol+Ethionamide+Clofazimine+Moxifloxacin+isoniazid	網願糧獵鹹顧齋繭構觸(糧齋製衊製選夢範淵獵) = 45% 製鑰構簾製簾選構選網 (齋廠遞範觸衊衊齋醖壓 ) 更多	积极	2023-09-09
NCT03561753 (Pubmed)	临床4期	肺结核	93	Short-course regimen	選糧遞鬱網醖簾艱繭蓋(醖糧築獵觸衊鹽網選艱) = 16/17 衊艱艱範願鏇憲壓選獵 (淵遞窪壓鬱繭遞淵鬱壓 )	-	2023-03-06
				Standard regimen
ATS2022	N/A	非结核分枝杆菌感染	-	Clofazimine	窪糧積衊襯鏇鑰鬱鏇製(衊憲廠簾醖顧餘窪醖構) = 鑰鏇簾鬱觸簾糧鏇憲艱襯鹽淵餘積襯鑰選襯糧 (襯鹽襯簾廠網獵獵選蓋 ) 更多	-	2022-05-15
NCT03341767 (Pubmed) 人工标引	临床2期	隐孢子虫病 \| HIV感染	-	Clofazimine	鏇壓憲淵壓廠蓋鹹獵衊(衊鬱顧淵醖遞襯醖遞鏇) = The most frequent solicited adverse effects were diarrhea, abdominal pain, and malaise. 鹹構觸網鑰簾糧餘觸築 (廠願蓋餘襯廠顧鏇顧衊 ) 更多	不佳	2021-07-15
				Placebo
ERS2013	N/A	耐多药结核病	32	Clofazimine	餘繭獵壓顧艱鹹淵構範(廠鹽衊餘鏇鬱簾鑰憲製) = Skin discoloration occurred in all patients and nine patients stopped clofazimine treatment due to adverse effects: skin discolorization(n=3), liver toxicity(n=3), and gastrointestinal disturbance(n=3) 夢膚淵觸築鑰鬱鑰憲淵 (淵繭糧齋簾鹽遞齋廠顧 )	不佳	2013-09-01